EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of neoadjuvant chemotherapy on the association between key genetic alterations and tumor microenvironment in upper tract urothelial carcinoma

Daiki Ikarashi, Kenta Takahashi, Shigehisa Kitano, Daichi Tamura, Masakazu Abe, Ayato Ito, Ei Shiomi, Shigekatsu Maekawa, Renpei Kato, Mitsugu Kanehira, Naoki Yanagawa, Wataru Obara

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04500-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Daiki Ikarashi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan. Hauptthemen laut MEDLINE: Tumor Microenvironment, Neoadjuvant Therapy, Carcinoma, Transitional Cell, Urologic Neoplasms. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Adjuvant nivolumab has demonstrated clinical benefit in urothelial carcinoma; however, emerging evidence suggests that its efficacy may differ between bladder cancer and upper tract urothelial carcinoma (UTUC), potentially reflecting differences in genomic profiles and the tumor microenvironment (TME). This study aimed to evaluate the association between key oncogenic mutations and the TME characteristics in UTUC, with a particular focus on the impact of neoadjuvant chemotherapy (NAC).

Methods

We analyzed tumor specimens from 32 patients who underwent nephroureterectomy for UTUC. Patients were categorized into NAC and non-NAC groups. Oncogenic mutations ( TP53 , FGFR3 , and RAS ) were assessed in all patients, and immune cell densities (CD3 + , CD4 + , CD8 + , Foxp3 + , and CD204 + ) in intratumoral and peritumoral regions were quantified using multiplex fluorescent immunohistochemistry.

Results

TP53 , FGFR3 , and RAS mutations were identified in 29%, 31%, and 34% of patients, respectively. NAC was administered to 22% of patients. The NAC group demonstrated significantly higher densities of intratumoral CD4 + T cells ( p = 0.0201) and a trend toward increased CD8 + T cells ( p = 0.0614). Among patients with TP53 mutations, NAC was associated with significantly higher intratumoral CD4 + T cell density ( p = 0.0369) compared without NAC. In contrast, FGFR3 -mutant tumors exhibited consistently low immune cell infiltration, irrespective of NAC status.

Conclusions

TP53 -mutant tumors from patients who received NAC were associated with higher intratumoral CD4⁺ T cell density, whereas FGFR3 -mutant tumors exhibited persistently low immune-cell infiltration irrespective of NAC exposure. These findings highlighted distinct mutation-associated TME features in UTUC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentNeoadjuvant TherapyCarcinoma, Transitional CellUrologic NeoplasmsHumansFemaleMaleAgedReceptor, Fibroblast Growth Factor, Type 3MutationMiddle AgedTumor Suppressor Protein p53Aged, 80 and over

Stichwörter der Autor:innen

FGFR3RASTP53NACTumor microenvironmentUpper tract urothelial carcinoma

Substanzen

Receptor, Fibroblast Growth Factor, Type 3Tumor Suppressor Protein p53FGFR3 protein, humanTP53 protein, human

Autor:innen und Institutionen

  • Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
  • Division of Cancer Immunotherapy Development, Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.
  • Division of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.
  • Division of Cancer Immunotherapy Development, Department of Advanced Medical Development, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. shigehisa.kitano@jfcr.or.jp.
  • Division of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. shigehisa.kitano@jfcr.or.jp.
  • Department of Pathology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.

Zitieren

APA

Ikarashi, D., Takahashi, K., Kitano, S., Tamura, D., Abe, M., Ito, A., Shiomi, E., Maekawa, S., Kato, R., Kanehira, M., Yanagawa, N., & Obara, W. (2026). Impact of neoadjuvant chemotherapy on the association between key genetic alterations and tumor microenvironment in upper tract urothelial carcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04500-1

Vancouver

Ikarashi D, Takahashi K, Kitano S, Tamura D, Abe M, Ito A, et al. Impact of neoadjuvant chemotherapy on the association between key genetic alterations and tumor microenvironment in upper tract urothelial carcinoma. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04500-1

BibTeX
@article{Ikarashi2026,
  author = {Ikarashi, Daiki and Takahashi, Kenta and Kitano, Shigehisa and Tamura, Daichi and Abe, Masakazu and Ito, Ayato and Shiomi, Ei and Maekawa, Shigekatsu and Kato, Renpei and Kanehira, Mitsugu and Yanagawa, Naoki and Obara, Wataru},
  title = {Impact of neoadjuvant chemotherapy on the association between key genetic alterations and tumor microenvironment in upper tract urothelial carcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04500-1}
}
Kostenlos starten →